抗肿瘤药物所致中性粒细胞减少患者感染预防指导专家共识

doi:10.3761/j.issn.0254-1769.2026.17.006

中华护理杂志 ›› 2026, Vol. 61 ›› Issue (17): 2345-2350.DOI: 10.3761/j.issn.0254-1769.2026.17.006

抗肿瘤药物所致中性粒细胞减少患者感染预防指导专家共识

中华护理学会肿瘤护理专业委员会, 上海市抗癌协会肿瘤护理专业委员会 (执笔：王心茹¹(), 张晓菊¹, 陆宇晗¹, 陆宇晗¹, 陆箴琦², 杨瑒)¹^,^*()

¹ 复旦大学附属肿瘤医院护理部，复旦大学上海医学院肿瘤学系上海市 200032
² 北京大学肿瘤医院护理部北京市 100142

收稿日期:2026-03-05 出版日期:2026-09-10 发布日期:2026-09-03
*通讯作者: 杨瑒，E-mail： yy-sandra@163.com
作者简介:王心茹：女，博士，主管护师，E-mail：wxrpumc@qq.com
基金资助:
上海抗癌协会护航计划(SACA-HH202401)

Expert consensus on guidance for infection prevention in patients with antineoplastic drug-induced neutropenia

Cancer Nursing Committee of Chinese Nursing Association, Cancer Nursing Committee of Shanghai Anti-Cancer Association (Writing Committee：WANG Xinru¹(), ZHANG Xiaoju¹, ZHANG Xiaoju¹, LU Yuhan¹, LU Zhenqi², YANG Yang)¹^,^*()

¹ Department of Nursing， Fudan University Shanghai Cancer Center，Department of Oncology，Shanghai Medical College，Fudan University， Shanghai 200032， China
² Department of Nursing， Peking University Cancer Hospital， Beijing 100142， China.

Received:2026-03-05 Online:2026-09-10 Published:2026-09-03
* Corresponding author: YANG Yang，E-mail： yy-sandra@163.com
Funding program:
Shanghai Anti-Cancer Association Nursing Support Program(SACA-HH202401)

1. “抗肿瘤药物所致中性粒细胞减少患者感染预防指导专家共识”全文.pdf(1203KB)

摘要/Abstract

摘要：

目的编制“抗肿瘤药物所致中性粒细胞减少患者感染预防指导专家共识”（以下简称“共识”），旨在为护士开展相关健康教育提供依据。方法成立“共识”编写小组，严格遵循世界卫生组织标准版指南制订流程，经文献检索、质量评价、证据提取及整合形成“共识”初稿。2025年6—10月，邀请20名肿瘤医疗或护理、血液系统疾病医疗或护理、医院感染管理、营养学、中医学、药学等领域的专家进行2轮函询，并组织18名专家进行论证，形成“共识”终稿。结果 2轮函询的有效问卷回收率均为100%，共收集228条修改意见，专家意见提出率分别为100%、90.00%；专家的权威系数分别为0.914、0.923；各条目的重要性评分均数分别为4.00~4.95、4.15~5.00分，变异系数分别为0.05~0.27、0~0.21；专家意见的肯德尔和谐系数分别为0.218、0.110（均P<0.001）。根据函询及论证专家建议修订“共识”内容，最终形成的“共识”包括治疗前感染风险告知、居家感染预防措施指导、症状监测与感染识别指导、用药指导、就医指导共5个方面的内容。结论该“共识”可为临床护士指导抗肿瘤药物所致中性粒细胞减少患者预防感染提供依据。

关键词: 抗肿瘤药物, 中性粒细胞减少, 感染预防, 自我管理, 肿瘤护理, 专家共识

Abstract:

Objective To develop an expert consensus on self-management guidance for infection prevention in patients with antineoplastic drug-induced neutropenia（hereinafter referred to as “consensus”），aiming to provide a reference for nurses to guide patients in self-managing infection prevention during neutropenia induced by antineoplastic therapy. Methods A “consensus” development group was established. In strict accordance with the World Health Organization standard guideline development process，a systematic literature search and quality assessment were conducted，and evidence on infection prevention self-management in patients with antineoplastic drug-induced neutropenia was extracted to form the initial draft of the “consensus”. From June to October 2025，2 rounds of expert consultation and a round of expert panel discussion were performed to revise and refine the “consensus”，resulting in the final version. Results The effective questionnaire response rate was 100% in both consultation rounds. A total of 228 revision suggestions were collected. The expert opinion submission rates were 100% and 90.00%；the expert authority coefficients were 0.914 and 0.923；and Kendall’s coefficients of concordance were 0.218 and 0.110（both P<0.001）. The mean importance scores of all items ranged from 4.00 to 4.95 and 4.15 to 5.00，with coefficients of variation ranging from 0.05 to 0.27 and 0 to 0.21，respectively. Based on expert suggestions from the consultations and panel discussion，the “consensus” was revised. The final “consensus” includes guidance on 5 aspects：pre-treatment infection risk communication，home-based infection prevention measures，symptom monitoring and infection identification，medication use，and healthcare seeking measures. Conclusion This “consensus” serves as a reference for clinical nurses to guide patients undergoing antineoplastic therapy in self-managing infection prevention during neutropenia.

Key words: Antineoplastic Drug, Neutropenia, Infection Prevention, Self-Management, Oncologic Nursing, Expert Consensus

中华护理学会肿瘤护理专业委员会, 上海市抗癌协会肿瘤护理专业委员会 (执笔：王心茹, 张晓菊, 陆宇晗, 陆宇晗, 陆箴琦, 杨瑒). 抗肿瘤药物所致中性粒细胞减少患者感染预防指导专家共识[J]. 中华护理杂志, 2026, 61(17): 2345-2350.

Cancer Nursing Committee of Chinese Nursing Association, Cancer Nursing Committee of Shanghai Anti-Cancer Association (Writing Committee：WANG Xinru, ZHANG Xiaoju, ZHANG Xiaoju, LU Yuhan, LU Zhenqi, YANG Yang). Expert consensus on guidance for infection prevention in patients with antineoplastic drug-induced neutropenia[J]. Chinese Journal of Nursing, 2026, 61(17): 2345-2350.

参考文献 43

[1]	Min KI, Byeon S. Diagnosis and management of neutropenia[J]. Blood Res, 2025, 60(1):30. DOI PMID
[2]	Leon Rapoport B, Garcia-Morillo M, Font C, et al. A prospective,real-world,multinational study of febrile neutropenia(FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN:a MASCC Neutropenia,Infection,and Myelosuppression Study Group initiative[J]. Support Care Cancer, 2023, 31(11):628.
[3]	周晓瑜, 潘政雯, 方珍珍, 等. 1例Ⅳ度骨髓抑制患者并发脓毒症性休克的护理[J]. 中华护理杂志, 2023, 58(13):1635-1639. DOI
	Zhou XY, Pan ZW, Fang ZZ, et al. Nursing care of a patient with grade Ⅳ myelosuppression complicated with septic shock[J]. Chin J Nurs, 2023, 58(13):1635-1639. DOI
[4]	刘英玲, 石会玲. 化疗不良反应的护理研究进展[J]. 中华护理杂志, 2004, 39(11):857-858.
	Liu YL, Shi HL. Research progress on nursing care of adverse reactions of chemotherapy[J]. Chin J Nurs, 2004, 39(11):857-858.
[5]	Chen YL, Zhou HH, Jiang JZ. Knowledge,attitude and practice towards chemotherapy-related neutropenia and febrile neutropenia among breast cancer patients[J]. BMJ Open, 2024, 14(10):e089738. DOI URL
[6]	钱会娟, 袁长蓉. 癌症自我管理研究现状及启示[J]. 中华护理杂志, 2010, 45(12):1147-1150.
	Qian HJ, Yuan CR. Research progress of self-management in cancer patients[J]. Chin J Nurs, 2010, 45(12):1147-1150.
[7]	杜世正, 袁长蓉. 自我管理模式的研究实践进展及思考[J]. 中华护理杂志, 2009, 44(11):1048-1051.
	Du SZ, Yuan CR. Research progress and thinking on self-management model[J]. Chin J Nurs, 2009, 44(11):1048-1051.
[8]	World Health Organization. WHO handbook for guideline development[M]. 2nd ed. Geneva: WHO Press, 2024.
[9]	Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE reporting checklist:a tool to improve reporting of clinical practice guidelines[J]. BMJ,2016:i1152.
[10]	周英凤, 胡雁, 朱政, 等. JBI循证卫生保健中心文本证据的质量评价清单[J]. 护士进修杂志, 2024, 39(10):1075-1080.
	Zhou YF, Hu Y, Zhu Z, et al. Critical appraisal checklist for textual evidence developed by JBI Center of Evidence-Based Health Care[J]. J Nurses Train, 2024, 39(10):1075-1080.
[11]	顾莺, 张慧文, 周英凤, 等. JBI循证卫生保健中心关于不同类型研究的质量评价工具:系统评价的方法学质量评价[J]. 护士进修杂志, 2018, 33(8):701-703.
	Gu Y, Zhang HW, Zhou YF, et al. JBI Evidence-Based Health Center’s quality assessment tool for different types of research:the quality evaluation of diagnostic and economic evaluation[J]. J Nurses Train, 2018, 33(8):701-703.
[12]	胡雁, 郝玉芳. 循证护理学[M]. 2版. 北京: 人民卫生出版社, 2018:31.
	Hu Y, Hao YF. Evidence-based nursing[M]. 2nd ed. Beijing: People’s Medical Publishing House, 2018:31.
[13]	王春青, 胡雁. JBI证据预分级及证据推荐级别系统(2014版)[J]. 护士进修杂志, 2015, 30(11):964-967.
	Wang CQ, Hu Y. JBI evidence pre-classification and evidence rank system(2014 edition)[J]. J Nurses Train, 2015, 30(11):964-967.
[14]	National Comprehensive Cancer Network. Hematopoietic growth factors(version 2025)[EB/OL]. (2025-11-05)[2026-03-01]. https://www.nccn.org.
[15]	de la Court JR, Bruns AHW, Roukens AHE, et al. The Dutch working party on antibiotic policy(SWAB) recommendations for the diagnosis and management of febrile neutropenia in patients with cancer[J]. Infect Dis Ther, 2022, 11(6):2063-2098. DOI PMID
[16]	Tralongo AC, Antonuzzo A, Pronzato P, et al. Management of chemotherapy-induced neutropenia in patients with cancer:2019 guidelines of the Italian Medical Oncology Association (AIOM)[J]. Tumori, 2020, 106(4):273-280. DOI URL
[17]	Heinz WJ, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin(FUO) in adult neutropenic patients:guidelines of the Infectious Diseases Working Party(AGIHO) of the German Society of Hematology and Medical Oncology(DGHO)[J]. Ann Hematol, 2017, 96(11):1775-1792. DOI PMID
[18]	Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia:ESMO clinical practice guidelines[J]. Ann Oncol, 2016, 27(suppl 5):v111-v118.
[19]	Centers for Disease Control Prevention. Core infection prevention and control practices for safe healthcare delivery in all settings[EB/OL]. (2024-04-12)[2026-03-01]. https://www.cdc.gov/infection-control/hcp/core-practices/index.html.
[20]	Wingard JR. Overview of neutropenic fever syndromes[EB/OL]. (2024-02-02)[2026-03-01]. http://61.153.6.101:11111/contents/overview-of-neutropenic-fever-syndromes.
[21]	Larson RA. Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia,myelodysplastic syndrome,and hematopoietic cell transplantation[EB/OL]. (2024-05-28)[2026-03-01]. http://61.153.6.101:11111/contents/use-of-granulocyte-colony-stimulating-factors-in-adult-patients-with-chemotherapy-induced-neutropenia-and-conditions-other-than-acute-leukemia-myelodysplastic-syndrome-and-hematopoietic-cell-transplantation.
[22]	Hibberd PL. Immunizations in adults with cancer[EB/OL]. (2024-10-21)[2026-03-01]. http://61.153.6.101:11111/contents/immunizations-in-adults-with-cancer.
[23]	Berliner N. Approach to the adult with unexplained neutropenia[EB/OL]. (2024-09-06)[2026-03-01]. http://61.153.6.101:11111/contents/approach-to-the-adult-with-unexplained-neutropenia.
[24]	Wingard JR. Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications[EB/OL]. (2025-07-31)[2026-03-01]. http://61.153.6.101:11111/contents/treatment-and-prevention-of-neutropenic-fever-syndromes-in-adult-cancer-patients-at-low-risk-for-complications.
[25]	Wingard JR. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults[EB/OL]. (2025-01-26)[2026-03-01]. http://61.153.6.101:11111/contents/prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults.
[26]	Wingard JR. Diagnostic approach to the adult cancer patient with neutropenic fever[EB/OL]. (2025-01-03)[2026-03-01]. http://61.153.6.101:11111/contents/diagnostic-approach-to-the-adult-cancer-patient-with-neutropenic-fever.
[27]	You ZX, Zhang HT, Huang YN, et al. Assessing the optimal regimen:a systematic review and network meta-analysis of the efficacy and safety of long-acting granulocyte colony-stimulating factors in patients with breast cancer[J]. Cancers, 2023, 15(14):3675. DOI URL
[28]	黄丽, 刘珂, 罗圣平, 等. PEG-rhG-CSF与rhG-CSF预防肿瘤化疗相关发热性中性粒细胞减少症的临床疗效及安全性比较的Meta分析[J]. 中国药物应用与监测, 2018, 15(5):264-269.
	Huang L, Liu K, Luo SP, et al. Meta-analysis of clinical efficacy and safety comparison of PEG-rhG-CSF and rhG-CSF for the prevention of febrile neutropenia associated with chemotherapy[J]. Chin J Drug Appl Monit, 2018, 15(5):264-269.
[29]	张华豪, 许银坤, 王一凡, 等. 八珍汤防治肿瘤放化疗所致骨髓抑制疗效的Meta分析[J]. 中国处方药, 2023, 21(8):95-100.
	Zhang HH, Xu YK, Wang YF, et al. Meta-analysis of Bazhentang in the treatment of bone marrow inhibition caused by radiotherapy and chemotherapy[J]. J China Prescr Drug, 2023, 21(8):95-100.
[30]	闫韶花, 许云, 闫蕴孜, 等. 口服中药改善结直肠癌辅助化疗所致骨髓抑制的系统评价和Meta分析[J]. 世界科学技术-中医药现代化, 2021, 23(5):1598-1609.
	Yan SH, Xu Y, Yan WZ, et al. Effectiveness of oral Chinese medicine for myelosuppression induced by adjuvant chemotherapy in patients with colorectal cancer:a systematic review and meta-analysis[J]. World Sci Technol Mod Tradit Chin Med, 2021, 23(5):1598-1609.
[31]	Amaral RAC, de Oliveira PP, da Fonseca DF, et al. Bundle for the prevention and management of complications of neutropenia in cancer patients[J]. Rev Bras Enferm, 2021, 74(2):e20200195. DOI URL
[32]	Jessop S, Harding E, Beaumont S, et al. Consensus guidelines for patient and carer education on neutropenic fever[J]. Intern Med J, 2025, 55(S7):136-152. DOI URL
[33]	Carmona-Bayonas A, Jimenez-Fonseca P, de Castro EM, et al. SEOM clinical practice guideline:management and prevention of febrile neutropenia in adults with solid tumors(2018)[J]. Clin Transl Oncol, 2019, 21(1):75-86. DOI PMID
[34]	中国医师协会肿瘤医师分会, 中国抗癌协会肿瘤临床化疗专业委员会, 《中华医学杂志》编辑委员会. 中国重组人粒细胞集落刺激因子在肿瘤化疗中的临床应用专家共识(2015年版)[J]. 中华医学杂志, 2015, 95(37):3001-3003.
	Chinese Medical Doctor Association Oncology Branch, China Anti-Cancer Association Tumor Clinical Chemotherapy Professional Committee, Editorial Board of the Chinese Medical Journal. Expert consensus on clinical application of recombinant human granulocyte colony stimulating factor in tumor chemotherapy in China(2015 edition)[J]. Natl Med J China, 2015, 95(37):3001-3003.
[35]	中华医学会血液学分会红细胞疾病学组. 中性粒细胞减少症诊治中国专家共识[J]. 中华医学杂志, 2022, 102(40):3167-3173.
	Red Blood Cell Disease Study Group, Hematology Branch of the Chinese Medical Association. Expert consensus on diagnosis and treatment of neutropenia in China[J]. Natl Med J China, 2022, 102(40):3167-3173.
[36]	张英丽, 张师前. 妇科恶性肿瘤放化疗期间应用聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)的中国专家共识(2023年版)[J]. 肿瘤药学, 2023, 13(1):1-10.
	Zhang YL, Zhang SQ. Chinese expert consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) during chemoradiotherapy for gynecological malignancies(2023 edition)[J]. Anti Tumor Pharm, 2023, 13(1):1-10.
[37]	中国临床肿瘤学会指南工作委员会. 抗肿瘤治疗所致中性粒细胞减少症诊断、预防和治疗指南[M]. 北京: 人民卫生出版社, 2025.
	Guidelines of Chinese Society of Clinical Oncology. Diagnosis,prevention,and management of antitumor therapy-induced neutropenia[M]. Beijing: People’s Medical Publishing House, 2025.
[38]	中国临床肿瘤学会中西医结合专家委员会. 抗肿瘤药物引起骨髓抑制中西医结合诊治专家共识[J]. 临床肿瘤学杂志, 2021, 26(11):1020-1027.
	Integrated Traditional Chinese and Western Medicine Expert Committee of Chinese Society of Clinical Oncology. Expert consensus on the diagnosis and treatment of integrated Chinese and Western medicine for myelosuppression caused by antitumor drugs[J]. Chin Clin Oncol, 2021, 26(11):1020-1027.
[39]	马军, 秦叔逵, 朱军, 等. 硫培非格司亭临床应用专家共识[J]. 临床肿瘤学杂志, 2020, 25(5):461-465.
	Ma J, Qin SK, Zhu J, et al. Expert consensus on clinical application of mecapegfilgrastim[J]. Chin Clin Oncol, 2020, 25(5):461-465.
[40]	中国中西医结合学会血液病专业委员会. 肿瘤放化疗后白细胞减少症中西医结合治疗专家共识(2022年版)[J]. 中华肿瘤防治杂志, 2022, 29(23):1641-1646,1652.
	Hematology Committee of Chinese Association of Integrated Traditional and Western Medicine. Expert consensus on the treatment of leukopenia after tumor radiotherapy and chemo-therapy with integrated traditional Chinese and Western medi-cine(2022 edition)[J]. Chin J Cancer Prev Treat, 2022, 29(23):1641-1646,1652.
[41]	中国抗癌协会肿瘤临床化疗专业委员会. 肿瘤治疗相关骨髓抑制院外管理专家共识(2025版)[J]. 中华医学杂志, 2025, 105(11):793-804.
	Tumor Clinical Chemotherapy Professional Committee of China Anti-Cancer Association. Expert consensus on the out-of-hospital management of myelosuppression associated with oncological treatment(2025 edition)[J]. Natl Med J China, 2025, 105(11):793-804.
[42]	刘波, 张宏艳. 肿瘤相关发热性中性粒细胞减少预防中国专家共识(2024年版)[J]. 中国新药杂志, 2025, 34(14):1457-1464.
	Liu B, Zhang HY. Consensus on clinical prevention of tumor therapy-related febrile neutropenia in China(2024 edition)[J]. Chin J New Drugs, 2025, 34(14):1457-1464.
[43]	National Cancer Institute. Common terminology criteria for adverse events(CTCAE) v6.0.[EB/OL]. (2025-07-22)[2026-03-01]. https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v6.pdf.

抗肿瘤药物所致中性粒细胞减少患者感染预防指导专家共识

Expert consensus on guidance for infection prevention in patients with antineoplastic drug-induced neutropenia

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

编辑推荐

Metrics

[1]	陈淑萍, 谢宝缘, 陈绵绵, 李美玲, 林翠芬. 淋巴瘤患者化疗随访方案的构建及应用研究[J]. 中华护理杂志, 2026, 61(6): 725-732.
[2]	朱静, 孙艳, 司惠芳, 李秀娟, 加米娜·瓦合甫, 常海霞. 成人急性白血病患者化疗期间心理弹性的变化轨迹及影响因素研究[J]. 中华护理杂志, 2026, 61(6): 741-748.
[3]	王雪娇, 蒋玲, 马倩, 李现文, 张彦, 吕亚, 施晓芸. 育龄期宫颈癌患者家庭支持方案的构建及应用研究[J]. 中华护理杂志, 2026, 61(6): 806-813.
[4]	中华护理学会人文护理专业委员会, 中华护理学会急诊护理专业委员会, （执笔：刘义兰, 汪唯, 甘秀妮, 朱陈萍, 杨霞, 熊莉娟, 朱丽辉, 徐翠荣, 郭舒婕, 张洁, 金晓燕, 李君, 李丽, 黄素芳, 王晓洁, 周晨曦, 李映兰. 对急诊科护士的人文关怀策略专家共识[J]. 中华护理杂志, 2026, 61(5): 612-615.
[5]	中国抗癌协会肿瘤康复整合护理专业委员会, （执笔：钟就娣, 王影新, 刘飞, 潜艳, 康璐, 颜红艳, 杨明雪, 廖洋洋, 刘群红. 老年肺癌患者术后分级运动的专家共识[J]. 中华护理杂志, 2026, 61(5): 616-621.
[6]	中华医学会骨科学分会护理学组执笔：梅迎雪, 韩梦月, 潘韩丽, 韩冰, 杨旭. 骨科大手术患者静脉血栓栓塞症预防专家共识[J]. 中华护理杂志, 2026, 61(4): 437-441.
[7]	杜姝姝, 曹亚琴, 闵继康, 冯悦, 吴琦, 蒋凤仙. 骨质疏松椎体压缩性骨折患者术后自我管理方案的构建及应用研究[J]. 中华护理杂志, 2026, 61(4): 442-451.
[8]	潘圆圆, 王董慧, 傅慧琳. 基于信息框架效应的垂体瘤患者自我管理行为干预方案的应用研究[J]. 中华护理杂志, 2026, 61(4): 475-482.
[9]	祝海香, 李艳, 许启锦, 陈瑾萱, 韩小雪, 吴缘. 慢性心力衰竭患者分级分类症状识别工具的研制及应用研究[J]. 中华护理杂志, 2026, 61(2): 149-156.
[10]	丁佳蓉, 陈慧, 王雪瑞, 孙小玲, 张银. 原位新膀胱术后尿失禁患者自我管理体验及需求的纵向质性研究[J]. 中华护理杂志, 2026, 61(2): 205-212.
[11]	国家儿童医学中心儿科护理联盟小儿神经内科学组 (执笔：宁佩, 崔璀, 李双子, 张楠, 夏思洁, 项雅玲, 谢园). 青少年癫痫患者过渡期准备护理实践专家共识[J]. 中华护理杂志, 2026, 61(17): 2351-2357.
[12]	陈琳琳, 林以扬, 罗文婷, 陈付红. 肺癌患者失志综合征相关因素的计算机模拟网络分析及护理启示[J]. 中华护理杂志, 2026, 61(17): 2404-2410.
[13]	蒋艳琳, 侯梦晓, 张桂菊, 汤玉梅. 虚拟现实干预对结直肠癌造口患者出院准备度与自我管理能力影响的研究[J]. 中华护理杂志, 2026, 61(16): 2165-2173.
[14]	中华护理学会肿瘤护理专业委员会（执笔：林细铃, 王丽英, 王海燕, 覃惠英, 石思梅, 李佳）. 日间化疗患者居家自我管理指导专家共识[J]. 中华护理杂志, 2026, 61(15): 2061-2068.
[15]	重庆市护理学会西藏护理学会（执笔任：洪艳, 潘龙芳, 唐萍, 冯家瑶, 林玲, 梁毅, 嘎多, 色吉那, 格桑罗布）. 高原成人低氧血症患者氧气吸入疗法护理专家共识[J]. 中华护理杂志, 2026, 61(15): 2069-2075.